Osteocytes are osteoblast-derived cells that are progressively entombed in mineralized matrix where they function to regulate skeletal homeostasis;their importance is highlighted both by their relative abundance and by their exceptionally long lifespan. Surprisingly, although osteocytes are known to manifest unique gene expression patterns relative to their osteoblast precursors and, as a consequence, display unique form and function, little is known of the molecular mechanisms that orchestrate their transition from the osteoblast or of the epigenomic and regulomic determinants that are responsible. In addition, although Wnt signaling is known to be a major but differential regulator of osteoblast and osteocyte activities, the majority of the gene targets that comprise the cell-specific activities of this pathway and the mechanisms through which TCF/LEF/b-catenin function to modulate these targets in both cell types remain unknown. Accordingly, the objectives of the first two aims are as follows.
Aim 1 : Identify the underlying epigenomic and regulomic mechanisms and associated molecular determinants that are responsible on a genome-wide scale for the osteoblast to osteocyte transition both in vitro and ex vivo.
Aim 2 : Examine and contrast the impact of the Wnt signaling pathway on osteoblast- and mature osteocyte-specific gene expression patterns and assess the molecular mechanisms through which these gene subsets are modulated directly by b-catenin and impacted by PTH and 1,25(OH)2D3 both in vitro and ex vivo. Our preliminary data and that of others have shown that a number of genes are upregulated during the osteocyte transition, including Sost, Fgf23, Tnfsf11, and Enpp1/3. The Sost gene, which encodes the Wnt pathway antagonist sclerostin (SCL), is of primary importance, however, due to its central biological actions on bone formation, its impact in disease, and its relevance as a potential therapeutic target. Progress has been made in understanding Sost regulation, prompted in part by the discovery that deletion of a downstream Sost enhancer alters Sost expression and is responsible for Van Buchem disease. Our preliminary data, however, suggest significant additional complexity, thus supporting the final objective of this proposal.
Aim 3 : Assess the molecular mechanisms that underlie both basal and regulated osteocyte expression of Sost at both epigenomic and regulomic levels in both in vitro and in vivo models. Osteocytes play unique roles in the skeleton and act in endocrine fashion to elaborate both local paracrine factors such as sclerostin and systemically active hormones such as FGF23. Pathologic consequences arising from aberrant osteocyte function can be catastrophic. Detailed basic insights arising from the proposed studies are likely to provide new routes of therapeutic intervention for a multiplicity of diseases that affect the skeleton.

Public Health Relevance

The osteocyte is an extremely important cell type within bone that functions in active skeletal remodeling and in the maintenance of mineral homeostasis. The studies herein seek to enhance our understanding of the mechanisms that underlie the origins and functions of this important bone cell such that better and more selective medicines can be created to prevent osteoporosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
1R01AR064424-01A1
Application #
8691297
Study Section
Skeletal Biology Development and Disease Study Section (SBDD)
Program Officer
Sharrock, William J
Project Start
2014-08-08
Project End
2019-07-31
Budget Start
2014-08-08
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$340,010
Indirect Cost
$115,010
Name
University of Wisconsin Madison
Department
Biochemistry
Type
Schools of Earth Sciences/Natur
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Onal, Melda; Carlson, Alex H; Thostenson, Jeff D et al. (2018) A Novel Distal Enhancer Mediates Inflammation-, PTH-, and Early Onset Murine Kidney Disease-Induced Expression of the Mouse Fgf23 Gene. JBMR Plus 2:32-47
Lee, Seong Min; Meyer, Mark B; Benkusky, Nancy A et al. (2018) The impact of VDR expression and regulation in vivo. J Steroid Biochem Mol Biol 177:36-45
Pike, J Wesley; Christakos, Sylvia (2017) Biology and Mechanisms of Action of the Vitamin D Hormone. Endocrinol Metab Clin North Am 46:815-843
St John, Hillary C; Hansen, Sydney J; Pike, J Wesley (2016) Analysis of SOST expression using large minigenes reveals the MEF2C binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D3 or TGF?1 responsiveness. J Steroid Biochem Mol Biol 164:277-280
Pike, J Wesley; Meyer, Mark B; Benkusky, Nancy A et al. (2016) Genomic Determinants of Vitamin D-Regulated Gene Expression. Vitam Horm 100:21-44
Meyer, Mark B; Benkusky, Nancy A; Pike, J Wesley (2015) Profiling histone modifications by chromatin immunoprecipitation coupled to deep sequencing in skeletal cells. Methods Mol Biol 1226:61-70
St John, Hillary C; Meyer, Mark B; Benkusky, Nancy A et al. (2015) The parathyroid hormone-regulated transcriptome in osteocytes: parallel actions with 1,25-dihydroxyvitamin D3 to oppose gene expression changes during differentiation and to promote mature cell function. Bone 72:81-91
Pike, J Wesley; Meyer, Mark B; St John, Hillary C et al. (2015) Epigenetic histone modifications and master regulators as determinants of context dependent nuclear receptor activity in bone cells. Bone 81:757-764
St John, Hillary C; Bishop, Kathleen A; Meyer, Mark B et al. (2014) The osteoblast to osteocyte transition: epigenetic changes and response to the vitamin D3 hormone. Mol Endocrinol 28:1150-65